I’m pulling this news post out by itself so its easier for people to find:
The second BAAM presentation of interest was on focused on a novel mTORC1 inhibitor which in the class of drugs called Piperazines. The drug, called Meclizine, (e.g. brand name Dramamine II) is a common over the counter (available for purchase without prescription) drug for motion sickness.
This research reports that Meclizine is an mTORC1 inhibitor that they identified and tested, and which in the NIA ITP program has been revealed to increased mice lifespans by approximately 15% (median lifespan) based on the preliminary data shown with about 75% of the mice deceased (note, this data may be from just one of the 3 ITP sites). The lifespan study is/was being done by Richard Miller and his groups in the ITP program, and the full results have not yet been published or announced. This news from the UC Davis research group is the first I’ve seen that has reported on the Meclizine impact on life extension increase.
The results with Meclizine have been good, but they are also looking for other drug targets within that general class of mTORC1 inhibitors for something that has a better binding affinity than Meclizine (binding affinity is a key measure of a drug’s ability to target a specific area, the tighter the binding, the fewer “off-target” effects).
Note: In the ITP 2019 study they have been testing 800 ppm in mice). My quick and dirty calculations suggest that 800ppm in mice equates to something like a dose of 300mg/day for a 72kg/160lb human. The key side effect of dramamine is “drowsiness”, so its generally considered a much more benign drug than rapamycin (which can have many negative side effects at high daily doses used in organ transplant and cancer patients).
Another person gave me this dosing calculation (from Louis:
My calculation shows that the ITP fed the mice a human equivalent dose of about 730mg of Dramamine per day for a 70kg person.
Here is the math: The ITP used 800ppm in food (see attached photo). And 800ppm is 0.08%. A typical mouse weighs about 0.025kg and eats about 4g of food per day, so 0.08% is 3.2mg of Dramamine for the mouse per day. That is a dose of 3.2mg/0.025kg=128mg/kg. Divide by 12.3 to allometrically scale to humans, to get a human equivalent dose of (128mg/kg)/12.3=10.4mg/kg. So for a 70kg human, that would be 728mg of Dramamine per day.
So Meclizine looks to be another drug for longevity that people may want to research. If Meclizine has no impact on mTORC2 in long term administration (it showed no mTORC2 inhibition in a short-term assay), it seems that a dosing strategy in humans that might be evaluated would be some sort of dosing combination of rapamycin and Meclizine. Since people only dose rapamycin for anti-aging once every week or two, perhaps there is a dosing strategy where Meclizine is dosed on some of the days that rapamycin is not taken, that would further increase lifespan and healthspan. This seems to be an area ripe for additional research and/or personal experimentation.
Note: Dr. Richard Miller mentioned the Meclizine studies they are doing in this recent podcast interview with him - I’ve queued up the video for where he discusses this at this link here.